Ristomycine monosulfate, ristocetin a base (balance principalement Ristocetin B), >=90% ristocetin base a (solde principalement Ristocetin B )

Code: r7752-100mg D2-231

Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

Ristomycin monosulfate has been used: to activate platelet and induce platelet aggregation to study the aggregation responses of platelets from buffalo, horse, pi...


en savoir plus

Votre prix
£636.00 100MG
DEMANDER

Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

Ristomycin monosulfate has been used: to activate platelet and induce platelet aggregation to study the aggregation responses of platelets from buffalo, horse, pig and sheep in in-house ristocetin cofactor von Willebrand factor (VWF:RCo) assay to measure glycoprotein Ib (GpIb) binding activity

Biochem/physiol Actions

Ristomycin possesses antibacterial activity. It may be used to diagnose von Willebrand disease and Bernard-Soulier syndrome. Ristocetin-induced platelet agglutination (RIPA) is decreased in patients undergoing chronic hemodialysis. Increased plasma glycocalicin levels (a product of enzymatic cleavage of GPIb) and decreased RIPA might reduce platelet adhesion to vascular subendothelium and improve bleeding associated with uremia in patients with chronic hemodialysis.

Ristocetin activates platelets. Ristocetin-induced platelet agglutination (RIPA) is decreased in patients undergoing chronic hemodialysis. Together with increased plasma glycocalicin levels (a product of enzymatic cleavage of GPIb), RIPA may contribute to diminished platelet adhesion to vascular subendothelium and increased bleeding associated with uremia. Addition of ristocetin and vWf caused specific agglutination of rGPIbα-liposomes suporting the potential use of rGPIbα-liposomes to enhance platelet function in vivo and support hemostasis in thrombocytopenic individuals.

General description

Ristomycin/ristocetin is a type III glycopeptide. It is a highly glycosylated glycopeptide, previously found inAmycolatopsis lurida.

Other Notes

Glycopeptide antibiotic complex

Packaging

100, 250 mg in poly bottle

assay≥90% ristocetin A basis (balance primarily Ristocetin B)
InChI keyVUOPFFVAZTUEGW-ZNAZZOOYSA-N
InChI1S/C95H110N8O44/c1-30-47(109)18-37-20-49(30)139-50-19-35(9-16-46(50)108)59(97)84(125)102-64-68(113)33-5-11-40(12-6-33)137-52-21-38-22-53(81(52)145-95-83(76(121)72(117)56(143-95)29-134-91-78(123)73(118)67(112)32(3)136-91)147-94-82(75(120)71(116)55(27-105)142-94)146-92-77(122)69(114)48(110)28-133-92)138-41-13-7-34(8-14-41)80(144-57-25-44(96)66(111)31(2)135-57)65-89(130)101-63(90(131)132-4)43-23-39(106)24-51(140-93-79(124)74(119)70(115)54(26-104)141-93)58(43)42-17-36(10-15-45(42)107)60(85(126)103-65)98-87(128)62(38)99-86(127)61(37)100-88(64)129/h5-24,31-32,44,48,54-57,59-80,82-83,91-95,104-124H,25-29,96-97H2,1-4H3,(H,98,128)(H,99,127)(H,100,129)(H,101,130)(H,102,125)(H,103,126)/t31-,32-,44+,48+,54+,55+,56+,57-,59+,60?,61-,62+,63?,64+,65-,66-,67-,68+,69+,70+,71+,72+,73+,74-,75-,76-,77-,78+,79-,80+,82-,83+,91+,92-,93+,94+,95-/m0/s1
mode of actioncell wall synthesis | interferes
Quality Level200
SMILES stringCOC(=O)[C@@H]1NC(=O)[C@H]2NC(=O)C(NC(=O)[C@@H]3NC(=O)[C@H]4NC(=O)[C@H](NC(=O)[C@H](N)c5ccc(O)c(Oc6cc4cc(O)c6C)c5)[C@H](O)c7ccc(Oc8cc3cc(Oc9ccc(cc9)[C@H]2O[C@H]C[C@@H](N)[C@@H](O)[C@H](C)O)c8O[C@@H]O[C@H](CO[C@@H]O[C@@H](C)[C@H](O)[C@@H](O)[C@H]O)[C@@H](O)[C@H](O)[C@H]O[C@H]O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]O[C@@H]OC[C@@H](O)[C@@H](O)[C@@H]O)cc7)cccc(O)c(c)-cc(O[C@@H]O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]O)cc(O)cc1
storage temp.2-8°C
Code
Description
Unité de vente
Prix annoncé
Qté
R7752-250MG
Ristomycine monosulfate, ristocetin a base (balance principalement Ristocetin B), >=90% ristocetin base a (solde principalement Ristocetin B )

Unité:250MG
Prix annoncé: £1,410.00
Source:Prix annoncé
AJOUTER
Cas Number11140-99-1
Ce produit répond aux critères suivants: